IP Library Granted Patent US 11,027,063
Granted Patent B2
US 11,027,063 · App. 15/870,703 · Granted Jun 8, 2021

Insulin delivery methods, systems and devices

Inventors: Bryan Mazlish (Palo Alto, CA); Lane Desborough (Thousand Oaks, CA)
Assignee: Bigfoot Biomedical, Inc.
A61M5/1723A61B5/14532A61M5/14248G16H20/17A61B5/4839A61K38/28A61M5/003A61M5/31568A61M2205/35A61M2205/502A61M2205/52A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,027,063
App. No.
15/870,703
Granted
Jun 8, 2021
Kind
B2
Abstract

An insulin delivery monitoring system that includes an insulin delivery device and a controller configured to perform or control performance of operations. A method of insulin delivery include determining a correction dose of insulin and triggering an alert.

Claims (61)

1. An insulin delivery monitoring system comprising:

an insulin delivery device configured to deliver insulin to a user; and

a controller configured to perform or control performance of operations, the operations comprising:

receiving notification of an amount of insulin delivered by the insulin delivery device;

determining a correction dose;

comparing the correction dose with a threshold insulin delivery amount; and

when the correction dose exceeds the threshold insulin delivery amount, triggering an alert to the user.

2. The insulin delivery monitoring system of claim 1 , wherein the controller is configured to base the correction dose on at least one of (1) a variance between an estimated blood glucose level of the user and a target blood glucose level of the user, (2) an insulin sensitivity factor of the user, or (3) an amount of insulin on board for the user, the insulin on board for the user based at least on the amount of insulin delivered by the insulin delivery device.

3. The insulin delivery monitoring system of any of claim 2 , further comprising a blood glucose monitoring device, the blood glucose monitoring device configured to detect the blood glucose level of the user and provide the blood glucose level to the controller, the estimated blood glucose level based on the blood glucose level.

4. The insulin delivery monitoring system of claim 1 , wherein the system is configured to base the threshold insulin delivery amount on an average total amount of daily basal insulin delivered to the user or a nominal basal rate for the user.

5. The insulin delivery monitoring system of claim 1 , wherein the system is configured to base the threshold insulin delivery amount on an estimate of an amount of insulin that would typically be administered to a user as basal insulin over a period of time between 1 hour and 3 hours.

6. The insulin delivery monitoring system of claim 1 , wherein the system is configured to include a static amount of insulin in the threshold insulin delivery amount.

7. The insulin delivery monitoring system of claim 1 , wherein the system is configured to include an amount of basal insulin delivered during a diurnal time period based on a personalized delivery schedule in the threshold insulin delivery amount.

8. The insulin delivery monitoring system of claim 7 , wherein the system is configured to include at least one delivery action at an amount greater than a baseline basal rate in the personalized delivery schedule.

9. The insulin delivery monitoring system of claim 1 , wherein the system is configured to base the correction dose on an equation including:

E

G

V

-

Target

I

S

F

-

I

O

B

10. An insulin delivery monitoring system comprising:

an insulin delivery device configured to deliver insulin to a user;

a blood glucose monitoring device, the blood glucose monitoring device configured to detect a blood glucose level of the user; and

a controller configured to perform or control performance of operations, the operations comprising:

receiving the blood glucose level from the blood glucose monitoring device;

determining a correction dose of insulin;

comparing the correction dose with a threshold insulin delivery amount; and

when the correction dose exceeds the threshold insulin delivery amount, triggering an alert to the user.

11. The insulin delivery monitoring system of claim 10 , wherein the operations of the controller further comprise estimating a future blood glucose level.

12. A method of insulin delivery monitoring, the method comprising:

receiving notification of an amount of insulin delivered by an insulin delivery device configured to deliver insulin to a user;

determining a correction dose of insulin with a controller in communication with a blood glucose level;

comparing the correction dose with a threshold insulin delivery amount with the controller; and

when the correction dose exceeds the threshold insulin delivery amount, triggering an alert to the user with the controller.

13. The method of claim 12 , further comprising receiving a blood glucose level of a user from a blood glucose monitoring device.

14. The method of claim 12 , further comprising basing the correction dose on at least one of a variance between an estimated blood glucose level of the user and a target blood glucose level of the user, an insulin sensitivity factor of the user, or an amount of insulin on board for the user, the insulin on board for the user based at least on the amount of insulin delivered by the insulin delivery device.

15. The method of claim 12 , further comprising enabling the user to customize the alert.

16. The method of claim 15 , wherein enabling the user to customize the alert comprises receiving a value relating to the threshold insulin delivery amount with the controller.

17. The method of claim 15 , wherein enabling the user to customize the alert comprises providing a factor relating to the sensitivity of an alarm.

18. The method of claim 12 , further comprising alerting the user that the correction dose of insulin is recommended.

19. The method of claim 18 , further comprising only determining the corrective dose when the user requests the corrective dose.

20. The method of claim 12 , further comprising basing the threshold insulin delivery amount on an average total amount of daily basal insulin delivered to the user or a nominal basal rate for the user.

Assignments (16)
SECURITY INTEREST Recorded Jan 10, 2025
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069870/0519 →
SECURITY INTEREST Recorded Jan 10, 2025
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069870/0456 →
SECURITY INTEREST Recorded Sep 30, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069074/0001 →
SECURITY INTEREST Recorded Sep 30, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069073/0912 →
SECURITY INTEREST Recorded Sep 24, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069030/0104 →
SECURITY INTEREST Recorded Sep 24, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069030/0296 →
SECURITY INTEREST Recorded Sep 23, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069019/0142 →
SECURITY INTEREST Recorded Sep 23, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069019/0188 →
SECURITY INTEREST Recorded Sep 12, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 068948/0172 →
SECURITY INTEREST Recorded Sep 12, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 068948/0324 →
SECURITY AGREEMENT SUPPLEMENT Recorded Sep 7, 2023
From: INSULET CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 064840/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2023
From: BIGFOOT BIOMEDICAL, INC.
To: INSULET CORPORATION
Reel/Frame 062900/0001 →
RELEASE OF SECURITY INTEREST Recorded Feb 17, 2023
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 062793/0316 →
SECURITY INTEREST Recorded Feb 10, 2023
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 062702/0145 →
SECURITY INTEREST Recorded Mar 12, 2021
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 055583/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2018
From: MAZLISH, BRYAN; DESBOROUGH, LANE
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 047074/0001 →
Continuity (4)
Provisional Application 62563804 · Sep 27, 2017
Provisional Application 62563836 · Sep 27, 2017
Provisional Application 62446236 · Jan 13, 2017
Related Publication 20180200440A1 · Jul 19, 2018
Cited By (6)
US 12,303,668 US 12,318,577 US 12,343,502 US 12,383,166 US 12,485,223 US 12,551,621